Drug intelligence / Profile preview

Trichomylin

Development stage: Phase 2
Lead developer: ZYUS Life Sciences
Modality: Small Molecules
Administration: Oral

Overview

**Trichomylin** is ZYUS Life Sciences' investigational oral, non-opioid cannabinoid pain medicine. It is a proprietary fixed-dose softgel formulation containing a balanced ratio of **cannabidiol**, **cannabichromene**, and **delta-9-tetrahydrocannabinol**, designed to modulate the endocannabinoid system for chronic-pain management. Clinical development has included a completed Phase 1 first-in-human SAD/MAD study and a Phase 2a study in moderate-to-severe cancer-related pain in patients with advanced cancer. ([zyus.com](https://www.zyus.com/2023-11-21-ZYUS-Life-Sciences-Corporation-Announces-Positive-Phase-I-Clinical-Trial-Results-for-Trichomylin-Softgels))

Brand names: Trichomylin
Other names: TrichomylinTrichomylin softgel capsulesTrichomylin softgels

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on Trichomylin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trichomylin.

Explore the full profile